The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and translational results from the phase 1 portion of the phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.
 
Jennifer Eads
Employment - Genmab (I); Janssen Oncology (I); Merus (I)
Stock and Other Ownership Interests - Janssen Oncology (I); Merus (I)
Honoraria - AstraZeneca
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo; Delcath Systems; Exelixis; Lantheus Medical Imaging; Lilly; Merck; Oncolys BioPharma; Tersera
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Chimeric Therapeutics (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Methods for treating a Cadherin 17 positive cancer
Travel, Accommodations, Expenses - Exelixis; Janssen Oncology (I); Merus (I)
 
Daniel Olson
Consulting or Advisory Role - Alphasights; Deciphera; Expert Consulting Services; Gerson Lehrman Group; Immunocore; Iovance Biotherapeutics; MJH Life Sciences; Novartis; Novartis; Obsidian Therapeutics; Replimune; SpringWorks Therapeutics
Research Funding - Bayer (Inst); Chimeric Therapeutics (Inst); CRISPRx (Inst); immatics (Inst); Immuneering (Inst); Immunocore (Inst); InhibRx (Inst); Takeda (Inst); TScan Therapeutics (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - Arcus Biosciences (Inst); AstraZeneca (Inst); Curio Science (Inst); CytomX Therapeutics (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Research Funding - 1200 Pharma (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Elicio Therapeutics (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Fog Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); IMPAC Medical Systems (Inst); Jazz Pharmaceuticals (Inst); Kura Oncology (Inst); Leap Therapeutics (Inst); Neogene (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Seagen (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Takeda (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Xianxin Hua
Stock and Other Ownership Interests - Sidocel, Inc
Consulting or Advisory Role - Chimeric Therapeutics
Research Funding - Chimeric Therapeutics
Patents, Royalties, Other Intellectual Property - I am a co-inventor of VHH1CDH17CAR that showed tumor suppressing activity in several preclinical models.
 
Amelia Langston
Consulting or Advisory Role - Moderna Therapeutics
Research Funding - Acepodia; Bristol-Myers Squibb/Celgene; Chimerix (Inst); Incyte (Inst); Indapta Therapeutics; Miltenyi Biotec; Novartis (Inst)
 
Ardaman Shergill
Honoraria - Biyantara Foundation; Cholangiocarcinoma Foundation; Colon Cancer Alliance; Colon Cancer alliance; Great Debates in GI cancers
Consulting or Advisory Role - Guardant Health; Ipsen; Iterion Therapeutics; Merus; Pfizer; Pfizer; Revolution Medicines; Takeda
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Ipsen; Merus; Revolution Medicines; Takeda
 
Rachael Purri
No Relationships to Disclose
 
Kimberly Hummel
No Relationships to Disclose
 
Stephanie Astrow
Employment - Chimeric Therapeutics; Fate Therapeutics
Stock and Other Ownership Interests - Chimeric Therapeutics
Travel, Accommodations, Expenses - Chimeric Therapeutics
 
Jason Litten
Employment - Chimeric Therapeutics
Leadership - Chimeric Therapeutics
Stock and Other Ownership Interests - Artiva
 
Daniel Halperin
Consulting or Advisory Role - Abbvie; Amryt Pharma; Boehringer Ingelheim; Camurus; Chimeric Therapeutics; Crinetics Pharmaceuticals; Exelixis; Harbour BioMed; Harpoon therapeutics; Ipsen; Isotopen Technologien; Lantheus Medical Imaging; Novartis; Progenics; Radiomedix; Sanofi Aventis GmbH; Tersera
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Chimeric Therapeutics (Inst); Crinetics Pharmaceuticals (Inst); Genentech/Roche (Inst); Isotopen Technologien (Inst); RayzeBio (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)